BRIUMVI’s New Data & Shifting MS Treatment Landscape
BRIUMVI has demonstrated robust efficacy in relapsing MS, and new long-term data bolster its profile. In Phase 3 trials (ULTIMATE I & II), ublituximab significantly outperformed an active comparator (teriflunomide) – showing lower annualized relapse rates and fewer MRI lesions (ir.tgtherapeutics.com). Now, six-year follow-up data from the extension of these trials are highly encouraging. According to a recent presentation at ECTRIMS 2025, 89.9% of BRIUMVI-treated patients remained free from disability progression after 6 years, and the annualized relapse rate (ARR) dropped to 0.012 – roughly one relapse per 83 patient-years (www.globenewswire.com). Moreover, no new safety signals emerged over that prolonged treatment period (www.globenewswire.com), underscoring durable efficacy and tolerability. These outcomes are on par with – or arguably better than – long-term results seen with Ocrevus, suggesting that BRIUMVI can provide sustained disease control for MS patients. Importantly, the drug’s rapid infusion (1 hour twice yearly) did not lead to unusual infusion-related issues; real-world Phase 4 data (ENABLE study) indicate the infusion experience in practice mirrors clinical trial safety, giving prescribers confidence in the shorter administration (www.globenewswire.com) (www.globenewswire.com).
Competitive positioning: BRIUMVI’s profile – high efficacy, convenient dosing, and now strong long-term data – positions it as a compelling alternative to established B-cell therapies. Its main competitors are Roche’s Ocrevus (IV twice-yearly) and Novartis’ Kesimpta (monthly at-home injection). While Kesimpta already offers the convenience of subcutaneous dosing, BRIUMVI’s twice-yearly schedule is less frequent, and the company is pursuing its own subcutaneous version. Notably, Roche is developing a subcutaneous Ocrevus, which reported positive Phase 3 data and could come to market soon (www.fiercepharma.com). That could erode BRIUMVI’s infusion-time advantage. However, TG Therapeutics is proactively responding – it has broadened its clinical program to include subcutaneous ublituximab and even a trial simplifying the initial dosing (consolidating the day 1 and day 15 infusions into one) (ir.tgtherapeutics.com) (www.biospace.com). In short, new data affirm BRIUMVI’s potential to shift MS treatment practices, encouraging earlier use of high-efficacy therapy. Physicians and patients may be more inclined to choose BRIUMVI given its demonstrated long-term protection against relapses and disability, especially if TG can maintain a favorable value proposition (short infusion time and potentially competitive pricing). According to Fierce Pharma, BRIUMVI’s list price was set lower than Ocrevus, which helped it rapidly achieve ~80% payer coverage within months of launch (www.fiercepharma.com) (www.fiercepharma.com). This combination of efficacy, convenience, and pricing could drive BRIUMVI to capture a growing share of the ~$10+ billion global MS market currently dominated by Ocrevus (which sold $3.6B in H1 2023 alone) (www.fiercepharma.com).
Financial Performance and Outlook
BRIUMVI’s commercial ramp in the U.S. has been strong, exceeding initial expectations. TG Therapeutics recorded $89 million in BRIUMVI net sales in 2023 (its first year post-launch) (ir.tgtherapeutics.com). For 2024, the company had guided for $220–$260 million in U.S. BRIUMVI revenue (ir.tgtherapeutics.com), but actual results topped that range significantly: full-year 2024 sales reached $310 million (with $103.6M in Q4 alone) (ir.tgtherapeutics.com). This reflects accelerating adoption as prescriber familiarity and insurance coverage grew throughout the year. The management characterized 2024 as “a year of significant outperformance and growth, highlighted by the strong adoption of BRIUMVI” (ir.tgtherapeutics.com). Looking ahead, TG is targeting ~$540 million in global revenue for 2025 (ir.tgtherapeutics.com) – implying nearly 75% year-over-year growth. This guidance likely includes continued U.S. momentum plus initial European sales (via partner). If achieved, BRIUMVI would be on a trajectory toward blockbuster status within just ~3 years of launch.
Profitability is emerging but remains modest as the company reinvests in commercialization. Thanks in part to substantial partnership income, TG posted a net profit of $12.7M in 2023 (ir.tgtherapeutics.com) and $23.4M in 2024 (ir.tgtherapeutics.com), essentially break-even on an operating basis. (The 2023 bottom line was aided by the one-time Neuraxpharm upfront payment of $140M (ir.tgtherapeutics.com), while 2024’s profit reflects improved operating leverage from higher sales.) On an adjusted basis, TG is now around cash-flow breakeven, and management expects to remain self-funded going forward. The company ended 2024 with a cash balance of $311 million (ir.tgtherapeutics.com), and it states that this cash plus projected BRIUMVI revenues “will be sufficient to fund [the] business based on [the] current operating plan” (ir.tgtherapeutics.com). In other words, no further equity dilutions or near-term financings appear necessary, which is a positive sign for shareholders after years of capital raises during the R&D phase. TG has even begun to generate positive EBITDA and operating cash flow in late 2024, indicating that incremental sales should increasingly drop to the bottom line as the MS franchise scales.
Dividend Policy and Shareholder Returns
As a growth-focused biotech, TG Therapeutics does not pay any dividend. In fact, the company explicitly states: “We have never declared or paid any cash dividends on our common stock” (www.sec.gov). All earnings and cash are being reinvested to fuel product launch, R&D, and debt servicing. Given its recent transition to profitability and ongoing investment needs (e.g. expanding BRIUMVI’s indications and pipeline development), no dividend is expected in the foreseeable future. Moreover, TG’s debt covenants restrict it from paying cash dividends at present (www.sec.gov). Investors in TGTX, therefore, should be seeking returns via stock price appreciation rather than income. The lack of dividend is typical for biotech companies at this stage, and management has signaled that this policy will hold until the business matures substantially (www.sec.gov). For context, TGTX’s dividend yield is 0%, and shareholders’ “return on investment” will come from growth in the company’s valuation tied to BRIUMVI’s success (or via a potential future acquisition, as discussed later).
Leverage, Debt Maturities, and Coverage
TG Therapeutics has moderate leverage after taking on debt to support BRIUMVI’s launch and growth. In August 2024, the company refinanced its prior venture debt and entered a new $250 million term loan facility with Blue Owl and HealthCare Royalty (www.sec.gov). This single-draw loan matures on August 2, 2029 (www.sec.gov), giving TG a long runway before principal repayment is due. The interest rate on the loan is floating (SOFR-based) with a margin starting at 5.50% and adjusting downward as BRIUMVI sales milestones are met (www.sec.gov). At current rates, the annual interest expense is roughly $24 million (2024 figure) – about 8% of 2024 revenues (ir.tgtherapeutics.com). The company can comfortably cover this interest from gross profits, though interest costs did weigh on earnings during early launch. As sales expand, interest coverage is improving: for example, Q4 2024 operating income (~$25M before taxes) slightly exceeded the quarterly interest expense (~$7M) (ir.tgtherapeutics.com) (ir.tgtherapeutics.com), and 2025’s growth should further increase coverage.
TG’s balance sheet is in solid shape. With $311M in cash and investments at 2024 year-end (ir.tgtherapeutics.com) and positive cash flow inflection on the horizon, the company has net cash (cash minus debt) of roughly $60M. Management anticipates existing capital and rising revenues will carry the company “into cash flow positivity” without needing new financing (ir.tgtherapeutics.com). Beyond the $250M term loan (which was used in part to refinance a prior Hercules Capital loan (www.sec.gov)), TG also negotiated an uncommitted $100M expansion facility as part of the deal for additional flexibility (www.sec.gov). This could be tapped for strategic needs, but so far remains unused. No other significant debt (e.g. convertible notes) is outstanding, and there are no near-term maturities to worry about. Overall, TG Therapeutics has leveraged its first commercial success to obtain low-cost capital, while keeping leverage at a manageable level (debt-to-equity ~1.1x, and net leverage effectively zero given the cash on hand). The 5-year term of the loan aligns with the period in which BRIUMVI is expected to ramp to peak sales, providing ample time for the company to either refinance under better terms or pay down debt from future profits.
Valuation and Comparables
TGTX shares have appreciated on optimism about BRIUMVI’s growth, giving the company a market capitalization around $4.6 billion as of early 2026 (companiesmarketcap.com). At this valuation, the stock trades at a rich multiple of current revenues – approximately 15× 2024 sales or ~8–9× expected 2025 sales (using the $540M revenue guidance). Such a multiple reflects the market’s anticipation of continued high growth and eventual “blockbuster” earnings from BRIUMVI. Traditional metrics like P/E are not very meaningful yet: using 2024 net income ($23M), the trailing P/E is well over 150×. However, this is common for emerging biopharma: investors are pricing in future earnings potential once the product reaches scale, rather than current GAAP profits. An often-used metric for pharma is EV/sales – TG’s enterprise value is about $4.5B (market cap minus net cash), which is roughly 8× 2025E sales. For comparison, large pharma companies with established MS franchises (e.g. Roche’s MS business) trade at lower multiples (closer to 4–6× sales for mature products), but TG offers higher growth off a smaller base. If BRIUMVI can continue to double revenues over the next couple of years, the valuation will progressively come down to more normalized levels.
In terms of competitive benchmarking, BRIUMVI is chasing a very large market. Roche’s Ocrevus is the market leader in MS B-cell therapy, with CHF 3.2B (~$3.6B) in sales in H1 2023 alone (www.fiercepharma.com) – implying an annual run-rate well above $7B. Novartis’s Kesimpta (launched 2020) had more than $1B in 2022 sales, growing rapidly. If BRIUMVI can capture even a moderate share of new MS patients or convert patients from these therapies, its sales could plausibly reach the high hundreds of millions or low billions (USD) annually in a few years. Sell-side analysts have indeed projected potential peak sales in the ~$1–2 billion range later this decade, assuming successful global adoption. At the current $4–5B market cap, investors appear to be discounting a significant ramp but not a full “best-case” scenario. This leaves room for upside if BRIUMVI exceeds expectations (for example, by expanding into primary progressive MS or other indications), but also downside risk if uptake stalls. It’s worth noting that TGTX’s valuation popped to these levels after the drug’s approval and early launch, but the stock has shown volatility around earnings reports. For instance, in mid-2023, TG’s stock plunged ~50% in one day when first-quarter sales ($16M in Q2 2023) came in slightly below buyside whispers (www.fiercepharma.com), illustrating the market’s high expectations. Since then, stronger sales trajectory and the ex-US deal have restored confidence. Overall, at ~8× forward sales, TGTX is priced for growth, inline with other single-product biotech peers, and continued execution on guidance will be key to supporting this valuation.
Risks and Red Flags
Investors should be aware of several risks and red flags related to TG Therapeutics and BRIUMVI:
- Heavy reliance on a single product: TG Therapeutics’ revenue is entirely from BRIUMVI, meaning the company’s fortunes rise and fall on this drug’s performance. Any setback – whether commercial, clinical, or regulatory – could severely impact the business. The company’s pipeline beyond BRIUMVI is nascent (early trials), so there’s little diversification at present. This concentration risk is inherent in many small biotechs, but is important to note.
- Intense competition in MS: The multiple sclerosis treatment landscape is very competitive, dominated by pharma giants. BRIUMVI, as a CD20-directed therapy, faces entrenched competitors like Ocrevus and Kesimpta. Roche and Novartis have far greater resources for marketing and for defending market share. New competitive threats are also emerging: for example, Roche’s subcutaneous Ocrevus is expected soon (Phase 3 data was positive) (www.fiercepharma.com), which could nullify one of BRIUMVI’s key advantages (short infusion time). Novartis’ Kesimpta is already capturing patients who prefer at-home injections. Additionally, oral MS therapies (like Merck’s evobrutinib, if approved, or existing S1P modulators) could compete for first-line use, potentially limiting BRIUMVI’s uptake to more refractory patients. Pricing pressure is another aspect – TG priced BRIUMVI below Ocrevus to drive adoption, which boosts volume but could cap margins or spark price competition. (www.fiercepharma.com)
- Clinical and safety risks: While BRIUMVI’s trial data and 6-year safety look good, all MS therapies carry risks that could emerge over a larger patient population. A notable class risk for anti-CD20 antibodies is Progressive Multifocal Leukoencephalopathy (PML) – a rare but serious brain infection. No PML cases have been seen in BRIUMVI patients to date, but PML has occurred with other MS therapies in this class (www.biospace.com), and vigilant monitoring is required. Should a safety scare occur (PML or severe infusion reactions, etc.), uptake could be dampened or regulators might impose warnings. Furthermore, long-term immunosuppression by B-cell depletion could have cumulative effects (e.g. infections, lowered immunoglobulins); any new safety signal could pose a red flag.
- Execution and scaling: TG Therapeutics is a relatively small company commercializing a drug in a global market – execution risk is non-trivial. Building out sales, medical affairs, and patient support in a competitive field is challenging. The early hiccup in Q2 2023 sales (when some prescriptions hadn’t converted to infusions as quickly as hoped) shows the complexities of MS drug initiation (www.fiercepharma.com). The company will need to maintain momentum, secure broad formulary coverage, and convince neurologists to keep prescribing BRIUMVI amid heavy industry marketing from rivals. Any slowdown in sales growth or failure to meet guidance would likely hurt the stock, as expectations are high.
- Financial and leverage risks: Taking on $250M of debt introduces financial risk, especially if sales were to disappoint. While current cash flow covers interest, a severe miss in revenue or unforeseen expenses could put pressure on covenants or necessitate further financing. Investors should watch TG’s interest coverage and the pace of cash generation. The term loan also has certain restrictions (e.g. on dividends, additional debt, etc.) (www.sec.gov) that limit financial flexibility until it’s repaid.
- Regulatory/management track record: A potential red flag is TG’s past regulatory setback. The company’s first approved drug, Ukoniq (umbralisib, a lymphoma PI3K inhibitor), was voluntarily withdrawn from the market in 2022 after data indicated safety issues (an increased risk of death in trials) (www.fiercepharma.com). The FDA subsequently rescinded Ukoniq’s approval (www.fiercepharma.com). That episode (in oncology) raised concerns about TG’s development decisions and cast management in a negative light at the time. To their credit, TG pivoted to focus on ublituximab in MS and achieved success there. Nonetheless, investors may view the Ukoniq incident as a red flag on management’s history. It underscores the importance of cautious drug development and post-market surveillance for TG’s products. Any similar missteps with BRIUMVI (e.g. an unexpected safety finding or regulatory non-compliance) would be very damaging.
- Limited pipeline and innovation risk: Beyond BRIUMVI, TG’s pipeline is thin. The company’s future growth likely requires either expanding ublituximab’s usage (new formulations, new indications) or successfully developing new therapies (like the early-stage CAR-T program). If these pipeline efforts do not bear fruit, TG could face a gap once BRIUMVI’s growth plateaus or its patents approach expiration. Larger competitors are advancing novel mechanisms (e.g. BTK inhibitors for MS, remyelinating therapies, etc.) – TG will need to innovate to stay relevant in the long run.
In summary, TG Therapeutics carries the typical risks of a one-product biotech, amplified by heavyweight competitors in its market. Investors should monitor competitive developments, BRIUMVI’s safety profile, and the company’s ability to execute on aggressive growth targets. The overall risk profile is somewhat balanced by the fact that BRIUMVI is already approved and generating revenue (reducing binary risk), and by TG’s improved financial footing post-launch.
Open Questions and Future Outlook
Despite the progress with BRIUMVI, several open questions remain for TG Therapeutics:
- Can BRIUMVI maintain its growth trajectory? Early sales have been strong, but will the uptake continue to scale toward blockbuster levels? The 2025 guidance of $540M global sales is ambitious – achieving it will require further penetration in the U.S. and a smooth rollout in Europe. Uptake in Europe is an open question: Neuraxpharm launched BRIUMVI in Germany in 1Q24 (ir.tgtherapeutics.com), but it remains to be seen how quickly other European markets follow and how the drug is received against established therapies in those countries. TG will earn royalties (and milestone payments) from ex-US sales (ir.tgtherapeutics.com), so ex-US performance will start contributing to the top line. Additionally, will neurologists switch stable patients from Ocrevus or Kesimpta to BRIUMVI, or will it mainly be used in newly diagnosed patients? TG’s ENHANCE Phase 3b trial is studying patients who switch from other CD20 therapies to BRIUMVI (ir.tgtherapeutics.com), and initial data (presented in late 2023) may help guide the company’s strategy in converting patients. How much market share BRIUMVI can ultimately capture – and whether its growth comes at the expense of Ocrevus/Kesimpta or from expanding the overall high-efficacy treatment pool – is a key question for the long term.
- How will the competitive landscape evolve? A major uncertainty is the impact of Roche’s subcutaneous Ocrevus. Roche reported that SC Ocrevus is non-inferior to IV on pharmacokinetics and MRI lesion outcomes (www.fiercepharma.com), and a regulatory filing could come soon. If approved, an injection option from the market leader might slow BRIUMVI’s momentum (since one of BRIUMVI’s main differentiators – infusion time – would be neutralized). On the other hand, as TG’s CEO noted, an under-the-skin injection might introduce new issues (like injection-site pain) and lacks long-term efficacy data on relapse reduction (www.fiercepharma.com), which could make some physicians hesitant initially. Novartis’ Kesimpta is another subcutaneous anti-CD20 that is already available; BRIUMVI competes by requiring only semi-annual dosing vs. monthly for Kesimpta. It remains an open question whether convenience or dosing frequency will win out in prescriber preferences. Additionally, new classes of MS therapies (e.g., BTK inhibitors in development) could change the treatment paradigm. TG will have to navigate these competitive dynamics. The next 1–2 years – as BRIUMVI and its rivals jostle for position and as new data (like head-to-head or real-world comparisons) emerge – will clarify how big a slice of the market BRIUMVI can secure.
- Will TG expand BRIUMVI into new indications? Currently, BRIUMVI is approved for relapsing forms of MS (RMS). Primary Progressive MS (PPMS) is a notable gap – Ocrevus holds an approval for PPMS, whereas BRIUMVI does not yet. Many wonder if TG will pursue a PPMS trial; this is a challenging indication (Ocrevus showed only modest benefits in PPMS), and TG has not announced a PPMS-specific ublituximab trial so far. Interestingly, TG’s partnered CAR-T candidate (azer-cel) will begin clinical trials in autoimmune diseases starting with PPMS (www.biospace.com), implying TG is exploring novel approaches for progressive MS. It’s an open question whether TG might eventually test BRIUMVI itself in PPMS or focus on azer-cel and other modalities for that population. Pediatric MS is another extension – the company has outlined a Phase 2 study design in children/adolescents (ULTIMATE Kids) (www.globenewswire.com), as BRIUMVI could be beneficial for aggressive pediatric cases if safety is shown. Any label expansions (pediatric MS, PPMS, neuromyelitis optica, or other autoimmune diseases) could broaden BRIUMVI’s market and are worth watching.
- When and how will TG introduce a subcutaneous (Sub-Q) BRIUMVI? The company has disclosed it is developing a Sub-Q formulation of ublituximab (ir.tgtherapeutics.com), which could be pivotal for remaining competitive long-term. The timeline and regulatory strategy for Sub-Q BRIUMVI are still unknown (likely a few years behind Roche’s effort). A Sub-Q version could allow TG to compete directly on convenience (e.g. an at-home injection), potentially negating Roche’s advantage if Ocrevus SC comes out first. The feasibility looks promising – ublituximab’s dosing could potentially be adapted to SC since other antibodies (ofatumumab/Kesimpta) have proven it can work for B-cell depletion. Investors will be keen to hear updates on the Sub-Q program’s progress in 2025–2026. Success here is an open question: Can TG launch Sub-Q BRIUMVI in time to protect its market share? If yes, it would strengthen BRIUMVI’s position; if delayed significantly, BRIUMVI might be locked as an IV-only option while competitors offer injections.
- Pipeline development and diversification: Beyond BRIUMVI, what’s next for TG Therapeutics? The company’s future mid- to long-term growth will depend on pipeline candidates like azer-cel or possibly acquiring/in-licensing new assets. Azer-cel (licensed from Precision BioSciences) is a bold venture – an allogeneic CD19 CAR-T cell therapy aimed at inducing long-term remission in autoimmune diseases (by depleting B cells even more profoundly/resetting the immune system). It’s slated to enter Phase 1 in 2025 (www.biospace.com). The concept is high-risk, high-reward and in very early stages. Investors should ask: will TG’s management, which has expertise largely in B-cell antibodies, be able to successfully develop a cell therapy? And even if the science works, can a small company commercialize such a complex product or will they need a partner? These are open questions that could shape TG’s trajectory post-2026. Similarly, TG has hinted at exploring ublituximab in autoimmune diseases beyond MS (possibly neurology-adjacent disorders) (www.biospace.com) – details are scarce, so it remains to be seen where they go next. Any pipeline wins could significantly diversify TG’s revenue stream and de-risk the reliance on BRIUMVI; conversely, lack of progress would mean TG eventually becomes an MS-focused single-product company, with growth tapering as that market saturates.
- Could TG Therapeutics be an acquisition target? Biotech investors often speculate on takeovers. With BRIUMVI now approved and generating substantial revenue, TG could be attractive to larger pharma companies looking to bolster their neurology portfolio. However, the ex-US Neuraxpharm deal complicates a potential acquisition in the short term – one reason TG’s stock dropped in Aug 2023 was belief that this deal “makes a potential acquisition of TG less likely”, according to an Evercore analyst (www.fiercepharma.com). Notably, TG did negotiate an option to buy back the ex-US rights if TG is acquired within two years (ir.tgtherapeutics.com), which preserves strategic flexibility. This clause expires around mid-2025, after which an acquirer would have to either work with Neuraxpharm or renegotiate those rights. The open question is: will TG remain independent to fully roll out BRIUMVI globally and develop its pipeline, or might it entertain a buyout if the price is right? Thus far, management (led by CEO Michael Weiss) seems intent on building an enduring company, and the recent financing moves suggest they are not reliant on a near-term sale. For investors, a buyout would be an upside kicker, but not something to count on given the current setup. In the meantime, TG’s focus will likely remain on execution and value creation as a standalone concern.
Bottom Line: TG Therapeutics has transformed over the past two years from an R&D-stage biotech into a growing commercial-stage company. BRIUMVI’s strong clinical data and accelerating sales underscore its potential to shift how relapsing MS is treated – offering patients an efficacious therapy with a convenient dosing schedule. The company’s financial profile is improving with revenue growth and adequate capital, though risks from competition and single-product dependence remain prominent. Investors should watch upcoming data readouts, competitive launches, and TG’s execution against its ambitious guidance. New BRIUMVI data (like the 6-year results) reinforce the drug’s value proposition; if TG can capitalize on this momentum and navigate the challenges ahead, TGTX could continue to deliver significant upside – but it will require skillful management and a bit of luck in a competitive, fast-evolving MS treatment landscape.
Sources: TG Therapeutics SEC filings and press releases; company investor presentations; Fierce Pharma and other financial media analyses.
References:
- TG Therapeutics FDA approval announcement for BRIUMVI (ir.tgtherapeutics.com); EU approval announcement (ir.tgtherapeutics.com) (ir.tgtherapeutics.com). - TG Therapeutics Q4 2023 and Q4 2024 Earnings/Business Updates (ir.tgtherapeutics.com) (ir.tgtherapeutics.com) (ir.tgtherapeutics.com). - TG Therapeutics–Neuraxpharm ex-US deal press release (ir.tgtherapeutics.com) (ir.tgtherapeutics.com); European launch news (ir.tgtherapeutics.com). - Long-term BRIUMVI efficacy data (6-year ULTIMATE I/II results) (www.globenewswire.com). - Fierce Pharma coverage of BRIUMVI’s launch and competitive landscape (www.fiercepharma.com) (www.fiercepharma.com) (www.fiercepharma.com). - TG Therapeutics 2024 10-K on dividend policy and debt covenants (www.sec.gov) (www.sec.gov). - TG Therapeutics 8-K on $250M term loan financing (maturity 2029) (www.sec.gov) (www.sec.gov). - BioSpace (company press) safety information on PML risk (www.biospace.com). - Fierce Pharma on TG’s withdrawal of Ukoniq due to safety issues (www.fiercepharma.com). - Market capitalization data as of Feb 2026 (companiesmarketcap.com).
